MA52675B1 - ANTI-STAPHYLOCOCCUS ANTIBODIES AND THEIR USES - Google Patents

ANTI-STAPHYLOCOCCUS ANTIBODIES AND THEIR USES

Info

Publication number
MA52675B1
MA52675B1 MA52675A MA52675A MA52675B1 MA 52675 B1 MA52675 B1 MA 52675B1 MA 52675 A MA52675 A MA 52675A MA 52675 A MA52675 A MA 52675A MA 52675 B1 MA52675 B1 MA 52675B1
Authority
MA
Morocco
Prior art keywords
antibodies
antigen
compositions
relates
binding fragments
Prior art date
Application number
MA52675A
Other languages
French (fr)
Other versions
MA52675A1 (en
Inventor
Christos Kyratsous
Alida Coppi
Brinda Prasad
Anna Zumsteg
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2019/062370 external-priority patent/WO2020106814A1/en
Publication of MA52675A1 publication Critical patent/MA52675A1/en
Publication of MA52675B1 publication Critical patent/MA52675B1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps spécifiques ou des fragments de liaison à l'antigène qui se lient à des antigènes staphylococciques, les anticorps et les fragments de liaison à l'antigène présentant une liaison fc atténuée à la protéine a ou à une protéine homologue. L'invention concerne également des compositions comprenant les anticorps et des procédés d'utilisation. Les anticorps et les compositions sont utiles pour traiter une infection staphylococcique, réduire des titres bactériens sériques ou rénaux, et traiter des symptômes associés à une infection staphylococcique. Les anticorps peuvent également prévenir la gravité et/ou la durée de la maladie primaire.The invention relates to specific antibodies or antigen-binding fragments which bind to staphylococcal antigens, wherein the antibodies and antigen-binding fragments exhibit attenuated fc binding to protein a or a homologous protein. The invention also relates to compositions comprising the antibodies and methods of use. The antibodies and compositions are useful for treating staphylococcal infection, reducing serum or renal bacterial titers, and treating symptoms associated with staphylococcal infection. Antibodies can also prevent the severity and/or duration of primary disease.

MA52675A 2018-11-21 2019-11-20 ANTI-STAPHYLOCOCCUS ANTIBODIES AND THEIR USES MA52675B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770608P 2018-11-21 2018-11-21
PCT/US2019/062370 WO2020106814A1 (en) 2018-11-21 2019-11-20 Anti-staphylococcus antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MA52675A1 MA52675A1 (en) 2021-12-31
MA52675B1 true MA52675B1 (en) 2023-06-28

Family

ID=79556180

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52675A MA52675B1 (en) 2018-11-21 2019-11-20 ANTI-STAPHYLOCOCCUS ANTIBODIES AND THEIR USES

Country Status (1)

Country Link
MA (1) MA52675B1 (en)

Also Published As

Publication number Publication date
MA52675A1 (en) 2021-12-31

Similar Documents

Publication Publication Date Title
MA35345B1 (en) Proteins of antigen binding with increased binding to fcrn
MA34527B1 (en) ANTIBODIES AGAINST METALLOPROTEINASE OF MATRIX 9
MA46731B1 (en) Anti-tmprss2 antibodies and antigen binding fragments
MA42622B1 (en) LIAISONS IN TIGIT AND THEIR USES
MA40801A1 (en) Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123
BR0207068A (en) Clfa protein monoclonal antibody, isolated antiserum, isolated antibody and humanized antibody containing said antibody, diagnostic kit comprising said antibody, method for diagnosing an infection with s.aureus, pharmaceutical composition for treating or preventing said infection , method for inducing an immune response, method for identifying monoclonal antibodies to clfa protein and active fragment isolated from s.aureus clfa protein a
MA31899B1 (en) Monoclonal antibodies are associated with hgm-csf and the medical structures they contain
MA37761A1 (en) Proteins for binding to a double receptor antagonist antigen and their uses
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
CN101218252A (en) Use of PANTON-VALENTINE leukocidin for treating and preventing staphylococcus infections
MA54975A1 (en) Anti-pcrv antibodies that bind to pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
MA38161A1 (en) Anti-bmp-6 Antibody
JP2019519546A5 (en)
JP2018507254A5 (en)
WO2020172621A8 (en) Cd33 antibodies and methods of using the same to treat cancer
Sepulveda et al. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents
MA52675A1 (en) Anti-staphylococcus antibodies and their uses
Müller et al. Resistance of Neisseria meningitidis to human serum depends on T and B cell stimulating protein B
CL2023003084A1 (en) Antistaphylococcus antibodies and their uses
Ngundi et al. Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action
MX2022006881A (en) Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l.
WO2021050857A8 (en) Anti-cd371 antibodies and uses thereof
Futse et al. Sequence and immunologic conservation of Anaplasma marginale OmpA within strains from Ghana as compared to the predominant OmpA variant
MX2021014882A (en) Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis.
Fusco et al. Defining potential vaccine targets of Haemophilus ducreyi trimeric autotransporter adhesin DsrA